Dapagliflozin (Forxiga®). HTA ID: 22030

Assessment Status Rapid review complete
HTA ID 22030
Drug Dapagliflozin
Brand Forxiga®
Indication Indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.
Assessment Process
Rapid review commissioned 09/05/2022
Rapid review completed 03/06/2022
Rapid review outcome A full HTA s not recommended. The NCPE recommends that dapagliflozin be considered for reimbursement*

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.